BW20030402002038  20030402T141729Z UTC


( BW)(IVAX-CORPORATION)(IVX) IVAX' Veterinary Subsidiary
Appoints Kwochka Vice President Research & Development

    Business Editors
    UK REGULATORY NEWS

    LONDON--(BUSINESS WIRE)--April 2, 2003--

DVM Pharmaceuticals, Inc., a wholly owned subsidiary of IVAX
Corporation (AMEX:IVX) (LSE:IVX.L), announces the appointment of
Kenneth W. Kwochka, DVM as vice president research & development. Dr.
Kwochka will report to Dr. Jane Hsiao, chairman and CEO of DVM
Pharmaceuticals, and vice chairman, technical affairs of IVAX
Corporation.

Dr. Kwochka is a Diplomate of the American College of Veterinary
Dermatology. Dr. Kwochka was an Associate Professor of
Medicine/Dermatology at the College of Veterinary Medicine, Department
of Veterinary Clinical Sciences at the Ohio State University for over
15 years. Dr. Kwochka brings extensive research experience in
veterinary medicine from academia, private practice and as a
consultant for leading industry drug manufacturers.

DVM Pharmaceuticals is engaged in the research, manufacture, sales
and marketing of veterinary pharmaceuticals for companion animals. DVM
has been a pioneer and leader in veterinary dermatology products, and
has expanded into other therapeutic categories. DVM is also involved
in the research and development of proprietary veterinary medicines
that capitalize upon the patented technologies and R&D pipeline of
those IVAX subsidiaries specializing in drug products for humans.

   Short Name: IVAX Corporation
   Category Code: UKS
   Sequence Number: 00003568
   Time of Receipt (offset from UTC): 20030402T142157+0100

    --30--ZW/uk* SM/uk

    CONTACT: IVAX Corporation

    KEYWORD: UNITED KINGDOM INTERNATIONAL EUROPE
    INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL 
    SOURCE: IVAX Corporation
  
Today's News On The Net - Business Wire's full file on the Internet
                          with Hyperlinks to your home page.
                          URL: http://www.businesswire.com